一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (455k)
Article in Japanese

Case Report

Re-exacerbation of immune-related lung injury following transient improvement with infliximab

Itaru Ohsawaa  Shojiroh Morinagab  Mamoru Sasakia  Tomoo Kakimotoa  Takashi Shimadaa  Naoto Minematsua 

aDepartment of Internal Medicine, Hino Municipal Hospital
bDepartment of Diagnostic Pathology, Hino Municipal Hospital

ABSTRACT

A 70-year-old male experienced immune-related lung injury that was refractory to corticosteroid therapy following administration of pembrolizumab as first-line treatment for non-small cell lung cancer. The lung injury transiently improved following treatment with infliximab but worsened two weeks later, leading to lethal respiratory failure. An autopsy revealed organizing and acute phases of diffuse alveolar damage, which presumably reflected the primary lung injury and its re-exacerbation, respectively. The withdrawal of infliximab might be associated with the re-exacerbation of the lung injury. The present case suggests that the administration of infliximab for recurrent immune-related lung injury should be considered.

KEYWORDS

Lung cancer  Immune-related adverse event  Lung injury  Immune checkpoint inhibitor (ICI)  Infliximab (IFX) 

Received 1 Sep 2020 / Accepted 22 Oct 2020

AJRS, 10(2): 139-143, 2021

Google Scholar